190 related articles for article (PubMed ID: 33580170)
1. Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies.
Stasenko M; Smith E; Yeku O; Park KJ; Laster I; Lee K; Walderich S; Spriggs E; Rueda B; Weigelt B; Zamarin D; Rao TD; Spriggs DR
Sci Rep; 2021 Feb; 11(1):3718. PubMed ID: 33580170
[TBL] [Abstract][Full Text] [Related]
2. Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.
Garg G; Gibbs J; Belt B; Powell MA; Mutch DG; Goedegebuure P; Collins L; Piwnica-Worms D; Hawkins WG; Spitzer D
BMC Cancer; 2014 Jan; 14():35. PubMed ID: 24447304
[TBL] [Abstract][Full Text] [Related]
3. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
Crawford A; Haber L; Kelly MP; Vazzana K; Canova L; Ram P; Pawashe A; Finney J; Jalal S; Chiu D; Colleton CA; Garnova E; Makonnen S; Hickey C; Krueger P; DelFino F; Potocky T; Kuhnert J; Godin S; Retter MW; Duramad P; MacDonald D; Olson WC; Fairhurst J; Huang T; Martin J; Lin JC; Smith E; Thurston G; Kirshner JR
Sci Transl Med; 2019 Jun; 11(497):. PubMed ID: 31217340
[TBL] [Abstract][Full Text] [Related]
4. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
[TBL] [Abstract][Full Text] [Related]
5. Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium.
Bruney L; Conley KC; Moss NM; Liu Y; Stack MS
Biol Chem; 2014 Oct; 395(10):1221-31. PubMed ID: 25205731
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo.
Zhang MX; Hong SS; Cai QQ; Zhang M; Chen J; Zhang XY; Xu CJ
Drug Deliv; 2018 Nov; 25(1):797-806. PubMed ID: 29542355
[TBL] [Abstract][Full Text] [Related]
7. Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth.
Rao TD; Fernández-Tejada A; Axelrod A; Rosales N; Yan X; Thapi S; Wang A; Park KJ; Nemieboka B; Xiang J; Lewis JS; Olvera N; Levine DA; Danishefsky SJ; Spriggs DR
ACS Chem Biol; 2017 Aug; 12(8):2085-2096. PubMed ID: 28617578
[TBL] [Abstract][Full Text] [Related]
8. Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive
Peplau E; De Rose F; Reder S; Mittelhäuser M; Scafetta G; Schwaiger M; Weber WA; Bartolazzi A; Skerra A; D'Alessandria C
Thyroid; 2020 Sep; 30(9):1314-1326. PubMed ID: 32200708
[No Abstract] [Full Text] [Related]
9. Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation.
Nemieboka B; Sharma SK; Rao TD; Edwards KJ; Yan S; Wang P; Ragupathi A; Piersigilli A; Spriggs DR; Lewis JS
Nucl Med Biol; 2020; 86-87():9-19. PubMed ID: 32403071
[TBL] [Abstract][Full Text] [Related]
10. Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma.
Yin P; Cui S; Liao X; Yao X
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328195
[TBL] [Abstract][Full Text] [Related]
11. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.
Thériault C; Pinard M; Comamala M; Migneault M; Beaudin J; Matte I; Boivin M; Piché A; Rancourt C
Gynecol Oncol; 2011 Jun; 121(3):434-43. PubMed ID: 21421261
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.
Comamala M; Pinard M; Thériault C; Matte I; Albert A; Boivin M; Beaudin J; Piché A; Rancourt C
Br J Cancer; 2011 Mar; 104(6):989-99. PubMed ID: 21326240
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
Aithal A; Junker WM; Kshirsagar P; Das S; Kaur S; Orzechowski C; Gautam SK; Jahan R; Sheinin YM; Lakshmanan I; Ponnusamy MP; Batra SK; Jain M
PLoS One; 2018; 13(4):e0193907. PubMed ID: 29708979
[TBL] [Abstract][Full Text] [Related]
14. ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody.
Sharma SK; Mack KN; Piersigilli A; Pourat J; Edwards KJ; Keinänen O; Jiao MS; Zhao H; White B; Brooks CL; de Stanchina E; Madiyalakan MR; Hollingsworth MA; Radhakrishnan P; Lewis JS; Zeglis BM
Clin Cancer Res; 2022 Mar; 28(5):948-959. PubMed ID: 34907079
[TBL] [Abstract][Full Text] [Related]
15. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
[TBL] [Abstract][Full Text] [Related]
16. Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition.
Yeku OO; Rao TD; Laster I; Kononenko A; Purdon TJ; Wang P; Cui Z; Liu H; Brentjens RJ; Spriggs D
Front Immunol; 2021; 12():663379. PubMed ID: 33936101
[TBL] [Abstract][Full Text] [Related]
17. Circ_MUC16 attenuates the effects of Propofol to promote the aggressive behaviors of ovarian cancer by mediating the miR-1182/S100B signaling pathway.
Yang H; Guo Y; Zhang Y; Wang D; Zhang G; Hou J; Yang J
BMC Anesthesiol; 2021 Nov; 21(1):297. PubMed ID: 34837947
[TBL] [Abstract][Full Text] [Related]
18. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse.
Wang Y; Cheon DJ; Lu Z; Cunningham SL; Chen CM; Luo RZ; Xing D; Orsulic S; Bast RC; Behringer RR
Differentiation; 2008 Dec; 76(10):1081-92. PubMed ID: 18637025
[TBL] [Abstract][Full Text] [Related]
19. [MUC16: The Novel Target for Tumor Therapy].
Gao R; Lou N; Han X; Shi Y
Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):452-459. PubMed ID: 35899441
[TBL] [Abstract][Full Text] [Related]
20. MUC16 suppresses human and murine innate immune responses.
Felder M; Kapur A; Rakhmilevich AL; Qu X; Sondel PM; Gillies SD; Connor J; Patankar MS
Gynecol Oncol; 2019 Mar; 152(3):618-628. PubMed ID: 30626487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
